Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.73 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.37 |
| ▸ | UGCG | Q16739 | 6/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3737852 | 0.90 | GHSR (0.63) | GHSRTACR1TRPV1MEN1KMT2A | |
| SCHEMBL3640188 | 0.84 | GHSR (1.00) | GHSRCCR3TACR1SMN1; SMN2 | |
| SCHEMBL3634475 | 0.84 | GHSR (0.71) | GHSRTACR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3637124 | 0.83 | GHSR (0.68) | GHSRTACR1LMNA | |
| Hydrochloric Acid SCHEMBL3740772 | 0.83 | GHSR (0.98) | GHSRCCR3TACR1SMN1; SMN2 | |
| SCHEMBL3634458 | 0.81 | GHSR (0.69) | GHSRCYP3A4TACR1LMNASLC1A3 | |
| SCHEMBL3638183 | 0.80 | GHSR (0.71) | GHSRCCR3TACR1LMNASMN1; SMN2 | |
| SCHEMBL3637108 | 0.80 | GHSR (0.62) | GHSRCCR3TACR1SMN1; SMN2 | |
| SCHEMBL3733869 | 0.79 | GHSR (0.48) | GHSRCCR3CYP3A4UGCGTACR1 | |
| SCHEMBL3634157 | 0.79 | GHSR (0.61) | GHSRCCR3TACR1SMN1; SMN2SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | claimed |
| EP-2167466-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | claimed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | claimed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2167466-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GIPR, GHSR, GLP1R | GHSR 2/4885MALT1 4345/4885CCR3 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.